NCT02878616View on ClinicalTrials.gov

Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 26, 2016

Primary Completion Date

July 19, 2017

Study Completion Date

July 19, 2017

Conditions
Kidney Transplantation
Interventions
DRUG

LFG316

LFG316 single dose

DRUG

IVIG

IVIG single dose

Trial Locations (1)

90048

Novartis Investigative Site, Los Angeles

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY